Alpha 2.0
Login Register
» Authors » Jodi Feser

Jodi Feser

Explore the profile of Jodi Feser including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 331
Followers 0
Related Specialties
Public Health
Infectious Diseases
Allergy & Immunology
Top 10 Co-Authors
Kathleen M Neuzil
Justin R Ortiz
Kristen D C Lewis
David I Bernstein
Doli Goswami
K Zaman
Mustafizur Rahman
Anthony A Marfin
W Abdullah Brooks
Florian Krammer
Published In
Vaccine
Lancet Glob Health
Vaccine X
Lancet Infect Dis
Nat Med
Affiliations
Soon will be listed here.
Recent Articles
1.
A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein
Bliss C, Nachbagauer R, Mariottini C, Cuevas F, Feser J, Naficy A, et al.
EBioMedicine . 2024 May; 104:105153. PMID: 38805853
Background: The development of a universal influenza virus vaccine, to protect against both seasonal and pandemic influenza A viruses, is a long-standing public health goal. The conserved stalk domain of...
2.
Antibody persistence and immune memory response following primary vaccination and boosting with live attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) in Bangladesh: A phase 4 open-label clinical trial
Zaman K, Yunus M, Aziz A, Feser J, Mooney J, Tang Y, et al.
Vaccine X . 2022 Mar; 10:100143. PMID: 35243320
Introduction: Japanese encephalitis (JE) virus is one of the leading causes of viral encephalitis across temperate and tropical zones of Asia. The live attenuated SA 14-14-2 JE vaccine (CD-JEV) is...
3.
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial
Nachbagauer R, Feser J, Naficy A, Bernstein D, Guptill J, Walter E, et al.
Nat Med . 2020 Dec; 27(1):106-114. PMID: 33288923
Seasonal influenza viruses constantly change through antigenic drift and the emergence of pandemic influenza viruses through antigenic shift is unpredictable. Conventional influenza virus vaccines induce strain-specific neutralizing antibodies against the...
4.
Persistence of IgM Antibodies after Vaccination with Live Attenuated Japanese Encephalitis Vaccine
Hills S, Van Keulen A, Feser J, Panella A, Letson G, Staples J, et al.
Am J Trop Med Hyg . 2020 Nov; 104(2):576-579. PMID: 33236716
Japanese encephalitis (JE) is a vaccine-preventable, mosquito-borne disease. Substantial progress with JE control in Asia has been made during the past decade, with most endemic countries now having JE vaccination...
5.
Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9-12 months of age in the Philippines: A non-inferiority Phase 4...
Capeding M, Alberto E, Feser J, Mooney J, Tang Y, Audet S, et al.
Vaccine X . 2020 Oct; 6:100074. PMID: 33005887
Introduction: Japanese encephalitis (JE) virus is the leading cause of viral encephalitis across temperate and tropical zones of Asia. The live attenuated SA 14-14-2 JE vaccine (CD-JEV) is one of...
6.
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial
Bernstein D, Guptill J, Naficy A, Nachbagauer R, Berlanda-Scorza F, Feser J, et al.
Lancet Infect Dis . 2019 Oct; 20(1):80-91. PMID: 31630990
Background: Influenza viruses cause substantial annual morbidity and mortality globally. Current vaccines protect against influenza only when well matched to the circulating strains. However, antigenic drift can cause considerable mismatches...
7.
Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naïve children in a randomized clinical trial in rural Senegal
Diallo A, Victor J, Feser J, Ortiz J, Kanesa-Thasan N, Ndiaye M, et al.
Vaccine . 2018 Sep; 36(43):6424-6432. PMID: 30224199
Introduction: Effective, programmatically suitable influenza vaccines are needed for low-resource countries. Materials And Methods: This phase II, placebo-controlled, randomized safety and immunogenicity trial (NCT01819155) was conducted in Senegal using the...
8.
Influenza Among Young Children in Bangladesh: Clinical Characteristics and Outcomes From a Randomized Clinical Trial
Rotrosen E, Zaman K, Feser J, Ortiz J, Goswami D, Sharmeen A, et al.
Clin Infect Dis . 2017 Oct; 65(11):1914-1920. PMID: 29028980
Background: Influenza causes substantial morbidity in children worldwide, although influenza vaccine is seldom used in low-resource settings. More information on the clinical presentation of influenza and the efficacy of vaccine...
9.
Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial
Brooks W, Zaman K, Lewis K, Ortiz J, Goswami D, Feser J, et al.
Lancet Glob Health . 2016 Oct; 4(12):e946-e954. PMID: 27746226
Background: The rates of influenza illness and associated complications are high among children in Bangladesh. We assessed the clinical efficacy and safety of a Russian-backbone live attenuated influenza vaccine (LAIV)...
10.
Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial
Victor J, Lewis K, Diallo A, Niang M, Diarra B, Dia N, et al.
Lancet Glob Health . 2016 Oct; 4(12):e955-e965. PMID: 27746224
Background: Live attenuated influenza vaccines have been shown to significantly reduce influenza in diverse populations of children, but no efficacy studies have been done in resource-poor tropical settings. In Senegal,...